S66 — Star Combo Pharma Share Price
- AU$16.21m
- AU$11.32m
- AU$24.99m
- 88
- 84
- 69
- 92
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.49 | ||
Price to Tang. Book | 0.5 | ||
Price to Free Cashflow | 23.95 | ||
Price to Sales | 0.63 | ||
EV to EBITDA | 5.44 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 3.5% | ||
Return on Equity | 1.47% | ||
Operating Margin | 5.18% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | 21.59 | 39.08 | 27.08 | 23.91 | 24.99 | n/a | n/a | 18.05% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Star Combo Pharma Limited is an Australia-based company that is primarily engaged in the manufacture and distribution of health and natural beauty products. The Company operates through two segments: Star Combo business and Austoyou retail. The Star Combo business segment includes developing, manufacturing, marketing and sales of natural health supplements and skincare products. The Austoyou retail business segment is made up of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers. The Company’s product categories include Costar, Living Healthy, Amax and J&K. The Company also provides Original Equipment Manufacturer (OEM) Services and Quality Assurance. The Company’s wholly owned subsidiaries include CoStar Pharma Laboratory Pty Ltd and Star Combo Australia Pty Ltd.
Directors
- Richard Allely NEC
- Su Zhang CEO
- Daniel Zheng CFO
- Star Zhang MDR
- Patrick Raper SEC
- Jialong Ding NED
- Wei Han NED
- Ziye Sui NED (42)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 4th, 2016
- Public Since
- May 16th, 2018
- No. of Shareholders
- 570
- Sector
- Specialty Retailers
- Industry
- Consumer Cyclicals
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 135,082,901
- Address
- Smithfield, 171 - 177 Woodpark Road, Sydney, 2164
- Web
- https://www.starcombo.com.au/
- Phone
- +61 297566555
- Auditors
- GCC Business & Assurance Pty Ltd
Upcoming Events for S66
Similar to S66
Accent
Australian Stock Exchange - SEATS
Adairs
Australian Stock Exchange - SEATS
Autosports
Australian Stock Exchange - SEATS
Baby Bunting
Australian Stock Exchange - SEATS
Beacon Lighting
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:20 UTC, shares in Star Combo Pharma are trading at AU$0.12. This share price information is delayed by 15 minutes.
Shares in Star Combo Pharma last closed at AU$0.12 and the price had moved by +9.09% over the past 365 days. In terms of relative price strength the Star Combo Pharma share price has outperformed the ASX All Ordinaries Index by +4.35% over the past year.
There is no consensus recommendation for this security.
Star Combo Pharma does not currently pay a dividend.
Star Combo Pharma does not currently pay a dividend.
Star Combo Pharma does not currently pay a dividend.
To buy shares in Star Combo Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.12, shares in Star Combo Pharma had a market capitalisation of AU$16.21m.
Here are the trading details for Star Combo Pharma:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: S66
Based on an overall assessment of its quality, value and momentum Star Combo Pharma is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Star Combo Pharma. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -2.91%.
As of the last closing price of AU$0.12, shares in Star Combo Pharma were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Star Combo Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Star Combo Pharma's management team is headed by:
- Richard Allely - NEC
- Su Zhang - CEO
- Daniel Zheng - CFO
- Star Zhang - MDR
- Patrick Raper - SEC
- Jialong Ding - NED
- Wei Han - NED
- Ziye Sui - NED